Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  hormone therapy
Results 1-25 of 3853 for your search:
Start Over
Enzalutamide, Radiation Therapy, and Hormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.461, NCI-2013-02283, 2013-027, 2970, NCT02023463
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Hormone Therapy and Docetaxel before Surgery and Radiation Therapy in Treating Patients with Newly Diagnosed Oligometastatic Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1618, NCI-2016-00836, CRMS-63459, IRB00070003, NCT02716974
Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CCRO025, NCI-2014-01486, 421870, NCT02064036
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140
LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-083, NCI-2014-00212, 1311012529, NCT02058706
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011H2301, NCI-2017-00678, NCT03081234
Endocrine Therapy Interruption in Increasing Risk of Recurrence in Younger Patients with Hormone Receptor-Positive, Stage I-III Breast Cancer Who Desire Pregnancy
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 to 42
Trial IDs: IBCSG 48-14/BIG 8-13, NCI-2015-01178, Alliance A221405/IBCSG 48-14, BIG 8-13 POSITIVE, IBCSG 48-14, A221405, NCT02308085
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Hormone Therapy and Radiation Therapy in Treating Patients with Non-metastatic, Intermediate, or High Risk Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 70 and over
Trial IDs: 10-625-A, NCI-2015-01652, NCT01342367
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
Exercise Training in Improving Quality of Life in Patients with Hormone Naïve Prostate Cancer Receiving Enzalutamide and Androgen Deprivation Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00053924, NCI-2014-02541, NCT02256111
Pexidartinib, Radiation Therapy, and Antihormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-075, NCI-2015-00742, 1501013723, NCT02472275
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCRN GU13-170, NCI-2017-00483, NCT02582749
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Enzalutamide and Leuprolide Acetate after Radiation Therapy in Treating Patients with High-Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15558, NCI-2015-01757, 147883, CC #15558, NCI-2015-01748, NCT02508636
Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: G200802, NCI-2016-00528, NCT02463032
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Ultra-hypofractionated Stereotactic Body Radiation Therapy with or without Short Course Degarelix in Treating Patients with Intermediate-Risk Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 16-1686, NCI-2017-00741, NCT03056638
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: G200901, NCI-2016-00279, NCT02368691
Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients with Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 135513, NCI-2015-01058, 14-13335, NCI-2015-00154, NCT02168062
Start Over